Minghui Pharmaceutical Ltd.
Location: China
Total raised: $131M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.08.2025 | Pre-IPO | $131M | OrbiMed |
Mentions in press and media 20
| Date | Title | Description |
| 16.06.2026 | Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Societ... | MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye disease At 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a 76% proptosis response at Week 24 in chroni... |
| 01.06.2026 | Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting | HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today ... |
| 11.08.2025 | Minghui Pharmaceutical Raises USD 131M in Pre-IPO Financing | Minghui Pharmaceutical, a Singapore-based clinical biopharmaceutical company, raised USD 131M Pre-IPO financing. The round was led by new investors OrbiMed and co-led by Qiming Venture Partners with participation from existing investor TF C... |
| 10.08.2025 | OrbiMed, Qiming lead $131m pre-IPO financing for late-stage clinical biopharma Minghui | Global healthcare investment firm OrbiMed and Qiming Venture Partners have jointly led a pre-IPO financing of $131 million in Minghui Pharmaceutical, a Chinese late-stage clinical biopharmaceutical company, according to a statement. Shangha... |
| 07.08.2025 | Minghui raises $131M 'pre-IPO' round to bankroll JAK inhibitor launch, ADC trials | Minghui Pharmaceutical has secured $131 million in what the company describes as a “pre-IPO” round to fuel the potential launch of its dermatitis cream in China as well as various clinical-stage oncology and immunology assets. The Shanghai-... |
| 07.08.2025 | Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion | SHANGHAI, Aug. 7, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led... |
| 20.05.2025 | Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC | SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully ... |
| 09.05.2025 | Minghui Pharmaceutical Announces Strategic Partnership and Licensing Agreement with Qilu Pharmaceutical to Develop B7-H3 ADC in Greater China | SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical ("Qilu&quo... |
| 29.11.2024 | Minghui Pharmaceutical Announces Positive Topline Results from Phase Ⅲ Trial of MH004 (Tofacitinib Etocomil) Ointment in Mild to Moderate Atopic Dermatitis | SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its phase Ⅲ tr... |
| 06.11.2024 | Minghui Pharmaceutical Announces Promising Initial Results from Phase I Clinical Trial of MHB039A, a Novel PD-1 x VEGF Bispecific Antibody, in Patients with Relapsed/Refractory Solid Tumors | SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company focused on developing transformative medicines in immunology and oncology, today announced initial results from its Phase I clinical... |
Show more